Aims-To develop a rapid PCR ELISA procedure for the detection of mutations in K-ras in a microtitre plate format, and to evaluate the assay for the detection of these mutations in human colorectal cancer.
Methods-An enriched PCR method was used with labelled primers, and PCR product was captured on GCN4 coated immunoassay plates. Detection of biotinylated mutant product was performed by colorimetric assay with streptavidin-horseradish peroxidase. The assay was used to determine K-ras status in a series of 60 human colorectal neoplasms, together with paired normal colonic mucosa. Results from gel electrophoretic analysis were compared with ELISA results. Results-The assay proved reliable in detecting K-ras mutations in DNA extracted from both fresh and paraffin embedded colorectal tumours. ELISA results were comparable with results from gel electrophoresis. Mutations of K-ras were detected in 16 Over the last eight years, many studies have confirmed the initial reports of frequent point mutation of the K-ras proto-oncogene in human colorectal neoplasms. l-3 It has been postulated that these mutations occur early in the course of colorectal carcinogenesis4 and that their detection may allow diagnosis of tumours at a stage where curative surgery is possible.5 Over the next few years, the likely development of treatments targeting the mutant K-ras product will provide even further impetus for the development of rapid and simple detection strategies.
Although there have been many published protocols for the detection of point mutations in the ras oncogene family, these protocols differ widely in their sensitivity and complexity.3
Typically these assays rely on polymerase chain reaction (PCR) amplification ofthe K-ras gene, with subsequent analysis of the product by a variety of methods. Early protocols allowed the detection of mutant alleles in 1-10% of cells. Assays that will be of use in a routine diagnostic laboratory will be not only be sensitive but robust, rapid, and specific. We have developed a new protocol for the detection of point mutations in codon 12 of K-ras which is suitable for automation. The protocol allows the selective amplification of mutant K-ras oncogenes from tumour tissue through the creation of unique restriction enzyme sites. A colorimetric plate assay is then used for the rapid analysis of mutant product. In this report, we describe the evaluation of the assay on a series of human colorectal neoplasms. DNA was extracted from the frozen tissues by first mincing them in a dry ice/methanol bath, then incubating the samples overnight at 48°C in a solution of 1% sodium dodecyl sulphate (SDS), 500,ug/ml proteinase K in 500 mM Tris, 20 mM ethylenediamine tetraacetic acid (EDTA), 10 mM NaCl, pH 9.0.18 Following phenol/chloroform extraction and ethanol precipitation, the DNA was resuspended in 10 mM Tris HC1 plus 1 mM EDTA, pH 8-0, and the DNA concentration was estimated by spectrophotometry. For the preparation of DNA from paraffin embedded tissues, 4 jm sections were cut from the blocks. After each block was cut the blade was washed with xylene in order to prevent cross contamination. Four sections were immersed in 400 VlI of extraction buffer (10 mM Tris HC1, pH 8-3, 50 mM KCl, 2-5 mM MgCl,, 0 45% Tween-20, and 0 5 mg/ml proteinase K),'5 incubated overnight at 55°C, and then boiled for 10 min. A 10 VI aliquot of the aqueous phase was used as the template in subsequent PCR reactions. In each instance, an adjacent section was stained with haematoxylin and eosin, and examined by light microscopy to confirm its histological appearance. DNA extracted from the colonic cancer cell line SW480, known to be homozygous mutant at codon 12 of the Kras oncogene,'9 was used as a positive control, while DNA from the homozygous wild type cell line K562 was used as a negative control.
MUTATION ANALYSIS
Mutations at the first and second bases of codon 12 of K-ras were detected using single tube allele specific enriched PCR followed by an ELISA assay. This protocol is represented schematically in fig 1 and not reach statistical significance in the small population analysed. In the four cases where an adenoma and carcinoma were collected from the same individual, two of the four carcinomas contained mutant K-ras, while all four of the adenomas contained only wild-type K-ras. DNA was extracted from paraffin sections of tumours known to be either mutant (n= 5) or wild (n= 5) for K-ras, together with sections from paired normal mucosa. For all samples, analysis using the single tube PCR ELISA gave results concordant with those obtained from fresh frozen specimens (data not shown).
To examine further the potential value of this assay in the diagnosis of colorectal carcinomas, its sensitivity and specificity for predicting disease status was determined at a variety of cut off points, as shown in table 3.
Discussion
Several enriched PCR methods have previously been described for the detection of mutant ras genes. We have sought to modify these protocols in order to make then more amenable to automation. Firstly, we have streamlined the protocol, so that two rounds of amplification and the intermediate digestion of the K-ras product can be performed in a single tube. This limits the need for the manipulation of reaction product, thereby reducing both the time and cost of the reaction and the likelihood of false positive results arising from carryover of PCR product. Secondly, the incorporation ofbiotin and GCN4 labels in the primers allows colorimetric detection of PCR products. While this does not increase the sensitivity ofdetection significantly in comparison to Nu-sieve gel electrophoresis, it does remove observer bias in the interpretation of assay results. Furthermore, the use of a microtitre plate format allows the rapid and simultaneous analysis of a large number of samples, thereby offering the potential for further reduction of the time and cost of analysis through automation.
Importantly, our assay also provides an inbuilt positive control for template amplification, through colorimetric analysis of an aliquot of the PCR reaction which has not been subject to final digestion with Bst NI. This is because an undigested sample will always generate a positive signal provided that amplification of the template, either wild or mutant, has occurred. Such an inbuilt control is important in distinguishing between reactions which are negative because of complete digestion of wild-type product, and those in which amplification ofa PCR product has failed to occur. These significant improvements in throughput and analysis have been gained without loss of sensitivity, as the protocol allows the detection of less than one mutant gene in a background of 1000 wild type genes, a degree of sensitivity similar to that already reported. '5 We determined the frequency of mutations at codon 12 of K-ras in an Australian population to be 33% for carcinomas and 42% for adenomas. Clearly, the use of an assay which also detects mutations at codons 13 and 61 is likely to have resulted in an increase in the frequency of detection of K-ras mutations, perhaps of the order of 5-10%.42l Likewise, any heterogeneity of K-ras mutations within the tumour may result in an underestimation of the true incidence of mutations in the tissues examined, although such heterogeneity has not been found in colorectal neoplasms. Nevertheless, our findings are in broad agreement with observations made from other populations using different assay techniques.'22 The frequency of K-ras mutations in adenomas has been shown to vary with size and histological classification,42223 although the relationship to size has not been reported by workers.24 Although such trends were noted in this study (table 2) , we were unable to show any significant associations because of the small numbers of adenomas assessed.
The assay was able to make a clear distinction between those carcinomas with normal K-ras and those with mutations of the oncogene at codon 12, an outcome consistent with the design of the test, which seeks to specifically enrich for K-ras mutations where those are present. While the results obtained from adenoma samples tended to cluster in the normal and mutant groups seen with carcinomas, two specimens showed results at an intermediate level (OD 055-060). It may be possible that these findings reflect amplification from a very small fraction of mutant cells within the tumours. Ifthis is so, then such a small population of mutant cells may occur much less commonly in carcinomas, as we found no results of an intermediate nature in this group. Such an observation is consistent with reports that mutations of K-ras occur early in the course of colorectal carcinogenesis. 4 It is noteworthy that no mutant K-ras was detected in 56 samples of normal mucosa. It has been reported that mutations of K-ras are present in seemingly normal mucosa from individuals with K-ras positive neoplasms,25 perhaps secondary to a field effect induced by unspecified carcinogens. The results in this study argue clearly against this possibility, at least in this Australian population.
While we have described this assay with reference to frozen and paraffin embedded tissues, its characteristics make it potentially useful for the automated screening of large numbers of samples, in which small numbers of mutant cells are present. One such example would be in the screening of faeces from patients known to be at risk of colorectal cancer.
When used to analyse frozen sections, our assay showed a high degree of specificity for colorectal cancer at cutoff points above OD 0 3 (table 3) . However, its sensitivity was clearly limited by the frequency of K-ras mutations in the tumours studied. Improvements in sensitivity ofthe assay may potentially be achieved by the analysis of additional oncogenic mutations. While these conclusions can only be justified if the results from frozen tissues are reproducible on faecal samples, it is encouraging that in preliminary studies we have been able to detect K-ras in faeces from patients with colorectal cancer. It is hoped that such strategies for the detection of oncogene mutations in colorectal neoplasms may one day provide a rational basis for therapeutic intervention.
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